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Abstract
Chagas disease, also known as American trypanosomiasis, is a neglected disease caused
by the protozoan parasite Trypanosoma cruzi. The disease affects about 6–7 million people
worldwide, mostly in Latin America. Although Chagas disease was discovered more than
100 years ago, and the first treatments over 40, only 2 drugs were used to treat this
pathology, it is still considered one of the neglected diseases. In this chapter, the subjects
related to conventional etiological therapies, benznidazole and nifurtimox, such as the
drug, the mechanism of action, the therapy schedule for treatment, efficacy and safety and
their adverse effects will be discussed. Additionally, it will address alternative therapies of
comorbidities related to the progression of Chagas’ disease in patients with chronic dis-
ease, such as heart disease and dysfunction of the digestive system. Finally, novel phar-
macological strategies and their related compounds will be reviewed accounting for their
progression in pharmacological studies and their success rate.
Keywords: Chagas disease, benznidazole, nifurtimox, symptomatic treatment, new
strategies
1. Introduction
Chagas disease or American trypanosomiasis is caused by the protozoan parasite Trypanosoma
cruzi (T. cruzi). Endemic largely in Latin American countries, it is transmitted primarily by
vectors, the insect vector triatomine, also known as “kissing bug”. It is estimated that 6–7
million people are infected worldwide, and that more than 10,000 people die each year as a
result of the disease, with the highest number of cases in Latin American countries [1].
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Although Chagas disease has been discovered more than 100 years ago, there are currently
only two drugs used to control Chagas disease (CD), benznidazole and nifurtimox [2–4].
Benznidazole has a similar efficacy profile to nifurtimox. They have high cure rates in the
acute phase and at the beginning of the chronic phase, being little or ineffective in the late
chronic phase [5]. Benznidazole and nifurtimox belong to the nitro heterocycles class of drugs;
however, each presents different mechanisms of action that are considered very aggressive and
may cause several adverse effects.
In the chronic phase of CD, the treatment at this stage aims to reduce parasitemia and prevent
complications that may lead to progression of visceral lesions. However, the administration of
benznidazole and nifurtimox remains controversial [5, 6]. To treat the cardiac and gastrointes-
tinal manifestations attributed to this phase of the disease, it requires specific pharmacological
approaches, highlighting the combination of diuretics, angiotensin-converting-enzyme inhibi-
tors or angiotensin receptor blockers, and adrenergic beta blockers. The choice of palliative
treatment is in relation to the symptoms of the patient.
Currently, the main treatment for CD is benznidazole and nifurtimox and both compounds are
effective in the acute phase to reduce parasitemia and the persistence and the clinical severity
of the disease [5]. However, in most countries, benznidazole is the primary choice to begin the
treatment, since it has shown less adverse events. The predominant reasons to use nifurtimox
are the occurrence of benznidazole resistance or its unavailability [6, 7]. Benznidazole can
achieve over 70% of cure in cases of congenital and acute phase, while nifurtimox reaches
80% efficacy. However, these compounds have limited efficacy in the chronic phase, with
efficacy rates of only 6–10% [8–10]. Treatment complications include, need for increasing
doses, duration varying according to the stage of infection, and high occurrence of adverse
effects caused by the long-term treatment with high doses. In addition, resistance may occur
depending on the Trypanosoma. cruzi (T. cruzi) strain [10].
Although the aforementioned therapy is over 40 years old, there are limitations in this first line
of treatment for CD. Several studies aimed to bring new options to its arsenal, mainly for the
chronic phase. Among them, are drugs used to treat other conditions, such as posaconazole,
and new compounds, such as E1224. Each of these has been tested in clinical trials. Other
strategies have been suggested as groundbreaking approaches to eradicate, or at least control,
CD. These include drugs, such as cruzipain and trypanothione reductase which specifically
targets the ergosterol biosynthesis pathway.
Considering this the classical treatment of CD, with a focus on the evaluation of efficacy and
safety of the current drug therapy, will be properly addressed in this chapter. In addition, a
review of new pharmacological therapies will be discussed.
2. Etiological treatment: benznidazole
2.1. Treatment history
Until the publication of the Manual de Doenças Tropicaes e Infectuosas in 1935 by Carlos
Chagas and Evandro Chagas (Manual of Tropical and Infectious Diseases), there was no
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pharmacological treatment available for trypanosomiasis. Drugs with trypanocidal activity
have been investigated by a number of researchers; however, without success [11]. In 1936,
quinolinic compounds were successfully used to treat an acute case of trypanosomiasis [12].
In the following years, nitrofurazone was administered to treat trypanosomiasis in mice
and achieve efficacy rates between 20 and 100%, depending on the therapeutic schedule
[13]. These results motivated the experimental trials in humans, in which nitrofurazone
demonstrated to be effective against trypanosomes in the circulating blood, cerebrospinal
fluids [14] as well as other promising clinical results [15, 16].
Novel studies were performed to identify an alternative therapeutic schedule and main side
effects [17, 18]. In 1962, Rio de Janeiro was the host city for the “Meeting of Debates on Chagas
Disease”, where the standardization of the methodology and establishment of criteria for the
evaluation of attempted pharmacological treatments was discussed. Nifurtimox and
benznidazole remain as the only two drugs available for treatment of CD [19].
2.2. The drug
Benznidazole (BNZ) N-benzyl-2-(2-nitro-imidazol-1-yl)acetamide (Figure 1) is a nitro heterocy-
clic drug. It was nitroimidazolic derivative synthesized in the early 1970s by Wineholt and
Liebman and produced by Hoffman-La Roche, Switzerland. In 2003, the rights and manufactur-
ing technology of BNZ was granted to the Laboratório Farmacêutico do Estado de Pernambuco
(LAFEPE) – Recife/PE – Brazil [5, 9, 10, 20, 21]. According to the Biopharmaceutical Classification
System, BNZ is categorized as class 4, thus exhibiting limited and/or variable absorption due to
the characteristics such as low solubility and low permeability. Therefore, there are interests in
strategies to improve the absorption rate, hence increasing its bioavailability [22, 23].
BNZ is administered orally in a tablet form of 100 mg for adults and 12.5 mg tablets for
children [24]. The drug is fully absorbed in the gastrointestinal tract and the plasma peak
concentration was achieved within 2–4 hours. The half-life is 12 hours and its metabolites were
eliminated in urine and feces [5, 10, 20].
2.3. Mechanism of action
The mechanism of action of BNZ is not fully understood [9, 25]. However, some reports
associate its action with the formation of free radicals and/or electrophilic metabolites. In the
nitroimidazole derivatives, the reduction of the nitro group (NO2) in the amino group (NH2)
Figure 1. Chemical structure of benznidazole.
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occurs by the action of nitroreductase present in protozoan cells or bacteria. This reaction leads
to the formation of radical intermediates, as well as electrophilic metabolites. The process is
initiated by the action of the enzyme NADPH cytochrome P450 reductase, which acts on the
nitro group (R-NO2) of the molecule nitroimidazole, inducing the production of an intermedi-
ate nitro radical (R-NO2) and the formation of hydroxylamine (R-NHOH). These intermediates
act on the covalent modification of macromolecules, such as DNA, causing fragmentation in
the chain and destabilization of the helix, inhibiting DNA synthesis leading to cell death of
protozoa parasitic and/or bacterial. In addition to this alteration in DNA, it involves the
modification of other macromolecules, such as lipids and proteins, affecting T. cruzi metabo-
lism. An additional mechanism of action of BNZ is the increase in phagocytosis, leading to
lysis and inhibition of T. cruzi growth through an interferon-gamma (IFN-γ)-dependent mech-
anism and through the enzyme NADH-fumarate reductase, respectively [9, 11, 26–28].
Concomitantly, the electrophilic metabolites mentioned above due to their high reactivity and
low specificity, may present human host action and cytotoxic effects observed during the
treatment of patients [27–29].
2.4. Therapeutic schedule
The dosage of BNZ in the acute phase of the disease should be provided in two or three
administrations daily, during the 60-day period. The dose is established according to the
patient’s age and weight. For adults, it is recommended 5 mg/kg/day, whereas for children
weighing less than 40 kg, 5–10 mg/kg/day is recommended. Furthermore for children, the
therapeutic regimen should be as small as possible to achieve therapeutic adherence. A recom-
mendation for infants is 10 mg/kg/day. In congenital infections, the treatment is indicated for
children born to mothers who were serologically positive for CD with the presence of T. cruzi
in umbilical cord blood, serum-specific IgM soon after birth, and IgG after 6 months. In the
newborn, the recommended etiologic therapy is the administration of BNZ twice a day for
30 days, it is suggested to be provided at 5 mg/kg/day [5, 11, 20, 30–32].
In the chronic phase, the dosage is 5–7 mg/kg/day divided into two administrations with an
interval of 12-hour between doses, and for 30–60 consecutive days [5, 20].
2.5. Efficacy and safety
It is considered as the first choice treatment because it exhibits a better safety and efficacy
profile when compared to nifurtimox. Moreover, there is evidence of greater efficacy [7, 28]. It
has antiprotozoal and antibacterial performance, acting against the trypomastigote and
amastigote forms [5].
In the acute phase, if the treatment is initiated immediately following the confirmation of the
presence of T. cruzi in the direct examination of the peripheral blood, the cure percentages are
greater than 70–80%, independent of the transmission route [5, 7, 9, 33]. It should be adminis-
tered to patients in the early chronic phase, children less than 12 years, laboratory accidents
and congenital infection. In newborns treated during the first year of life, the chances of cure
are greater than 90%; otherwise, in the late chronic phase the patient has lower chances of cure
(~10%) [20, 34–36].
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Two placebo-controlled clinical trials were performed in the USA in children between 6 and
12 years old for the evaluation of treatment using BNZ, in which the results were satisfactory.
In the first trial, 60% of the children treated had a change from positive to a negative in
serology for CD, compared to 14% of them receiving placebo. In the second trial, similar
results for children treated with BNZ showed a 55% change from a positive to a negative
antibody test, compared to 5% of those receiving placebo [37].
For treatment in cases of organ transplantation, it is essential to know if the donor or recipient
presents positive serology and can transmit or reactivate the infection. In cases of absolute
requirement for transplantation, the serum-reactive donor in which the recipient is serologi-
cally negative for a chagasic infection, the donor should receive BNZ therapy following the
traditional dosing regimen, within 60 days prior to transplantation. For the recipient following
transplantation, it is recommended to initiate therapy by performing serological tests over
time. There is a serum conversion with the treatment for the acute phase. If an acute infection
is detected, the treatment need to be started [38–40].
Immunocompromised patients, carriers of hematological malignancies, users of immunosup-
pressive drugs, or those co-infected with the acquired immunodeficiency virus may reactivate
CD. The treatment is the conventional treatment, lasting 60 days, and depending on the clinical
conditions of the patient, it may be increased to 90 days [40–42].
When accidental infection occurs, the individual who accidentally had contact with contami-
nated materials; needle puncture, contact in lesions, wounds or mucous membranes, or any
other means that indicates the possibility of having been infected by the parasite, is evaluated
by serological tests and treatment begins immediately. During the 10–15 days of the treatment
period, the serological tests will be repeated [5, 11].
At the beginning of the chronic phase in children, treatment follows the same reasoning for acute
phase cases in children younger than or equal to 12 years with positive serology. For adults,
therapy is recommended to prevent or reduce the progression of CD in more severe forms, such
as cardiomyopathy, and to prevent congenital transmission in pregnant women [5, 11, 20, 43]. Its
use in the chronic phase has generated vast discussions. The BENEFIT project – Benznidazole
Evaluation for Interrupting Trypanosomiasis, is an international multicenter, randomized,
double-blinded, placebo-controlled trial of BNZ for the treatment of patients with mild to
moderate Chagas cardiomyopathy. This study has conducted and produced results that indi-
cated that the use of BNZ in the chronic phase significantly reduced the detection of circulating
parasites; however, did not attenuate the cardiac clinical progression [20, 33].
Treatment for patients older than 50 years should take into account the risk of toxicity of the
drug against the benefits of the therapy individually [6, 20].
2.6. Adverse effects
Therapy with BNZ contains some challenges, such as the large doses administered, time
duration varying according to the stage of infection, and high occurrence of adverse effects.
These challenges are less frequent when compared with nifurtimox (Table 1). The adverse
effects in patients receiving BNZ may be classified into three groups: manifestations of
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hypersensitivity (dermatitis with rashes, generalized or peritoneal edema, fever, lymphade-
nopathy, muscle and joint pain), bone marrow depression (agranulocytosis, neutropenia, and
thrombocytopenic purpura), and peripheral polyneuropathy (paresthesias and polyneuritis)
[7, 11].
Adverse effects of dermatological cause appear in approximately 30% of the patients being
treated with the drug. Rashes occur due to photosensitization, dermatitis is usually mild to
moderate and may be treated with topical systemic corticosteroids. However, treatment
should be discontinued immediately in cases of severe or exfoliative dermatitis or associated
with fever and adenopathy. Bone marrow suppression is rare, but if occurs the treatment
should be discontinued immediately. Additional adverse effects include weight loss, nausea
and/or vomiting, anorexia, and insomnia [8, 11, 20, 29, 43].
Treatment is contraindicated in pregnancy and in patients with severe renal or hepatic impair-
ment [11, 20, 44].
According to the World Health Organization (WHO), the ideal requirements for treatment are:
parasitological cure in both phases (acute and chronic), effective doses in single or few doses, low
cost, no side effects or teratogenic effects, without hospitalization, and induction of resistance.
Until now, there is no drug for the treatment of CD that meets each of these WHO requirements.
3. Etiological treatment: nifurtimox
3.1. The drug
Nifurtimox (NFX) (Figure 2) belongs to the class of nitrofuran compounds. Her-Linger, Mayer,
Petersen and Bock from Bayer™ synthesized it in 1962 in Germany. This was the first drug
designed to treat trypanosomiasis, such as sleeping sickness and Chagas diseases [34]. Its
production was interrupted in 1980s due to the reduction on world demand [11]. In 2009, the
WHO Expert Committee on the Selection and Use of Essential Medicines recommends the
inclusion of NFX in the model list of essential medicines (EML) and Bayer resumed the
production of NFX [45]. Bayer, through WHO, still provides NFX worldwide in 120 mg and
30 mg tablets under the brand name Lampit [46], in United States and it is redistributed by
Center for Disease Control and Prevention (CDC) [47].
Adverse effects Benznidazole Nifurtimox
Anorexia and weight loss 5–40% 50–75%
Nausea 0–5% 15–50%
Vomiting 0–5% 15–26%
Peripheral neuropathy 0–30% 2–5%
Leukopenia Rare: <1% Rare: <1%
Table 1. Frequencies of adverse effects associated with benznidazole and nifurtimox.
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NFX is a 5-nitrofuran (3-methyl-4-(50-nitrofurfurylideneamine) tetrahydro-4H-1,4-tiazine-1,1-
dioxide. NFX possesses an asymmetric center, but it is used as a racemic mixture since pure
stereoisomers were not more active or less toxic.
NFX is well absorbed following oral administration. The plasma levels range from 10 to
20 mM and lower concentrations are found in urine and tissues. The therapeutic schedule
must vary according to the patient’s age and disease phase [9, 11, 48, 49].
3.2. Mechanism of action
The mechanism of action of NFX is based on cellular damage originating from the production
of nitro anion radical through two pathways: through a redox cycle with the formation of O∙
(superoxide anion) and its reduction to the corresponding amine derivative [50–52].
This mechanismwas thoroughly studied by Do Campo and colleagues [51, 53–58]. The reduction
of a nitro group by nitroredutase (NTR) is fundamental for NFX mechanism of action. This
enzyme catalyzes the reduction of 2-electrons of the compound, producing a nitrous intermedi-
ate, followed by a second 2-electron reduction to generate a hydroxylamine. This derivative can
directly lead to cell damage, or generate other cytotoxic agents (Figure 3) [52, 59]. Since the T.
cruzi detoxification mechanism is insufficient, it becomes more susceptive to reactive nitro com-
pounds [60–62]. The presence of the nitro reductase type I in the parasite is the main responsibil-
ity for NFX selectivity. This enzyme is absent in mammals, reducing the formation of toxic agents
in human.
3.3. Therapeutic schedule
Several therapeutic schedules were evaluated in the past years. The doses vary between 5 and
30 mg/kg/day, in extended therapies of 30–120 days [63–67]. Based on these experiments and
considering the efficacy/tolerance ratio, the ideal therapeutic schedule of NFX is 8–10 mg/kg/day
Figure 2. Chemical structure of nifurtimox.
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in adults and 15 mg/kg/day in children, for 60, 90 or 120 days, divided into three daily doses,
after meals [1, 68]. It must be highlighted that even at these doses, side effects may potentially be
present in adults.
3.4. Safety and efficacy
Many studies regarding the efficacy of NFX were performed between the 1960 and 1980s, at
the beginning of its development and first years of commercialization [5, 11, 34]. Considering
these studies, the activity of the NFX against the Trypanosoma sp. is expressive. NFX is capable
to achieve efficacy rates of 70–100% in acute parasitemia cases. However, these rates substan-
tially decrease when it comes to adult chronic phase, reaching values of only 7–8% in adults,
although in children under 14, it remains around 86% [68, 69].
The primary reason why BNZ is often preferred compared to NFX is due to the presence of
adverse effects. NFX frequently produces side effects [5, 11, 34, 70], but the majority are mild and
can be managed with dose reduction or temporary suspension of medication [11, 68, 71].
3.5. Adverse effects
The treatment of CD is long and continuous and the presence of adverse effects becomes quite
common between 60 and 100% of the patients [68]. The most frequent side effects described in
the case of NFX are anorexia, nausea, headache, and amnesia. The possible neurological
reactions are restlessness, disorientation, forgetfulness, insomnia, spasms, paresthesias, poly-
neuritis, and convulsive seizures. Most of the adverse effects (93%) are mild and disappear
through dose reduction or after suspending the treatment [68, 70].
4. Symptomatic treatment of chronic phase
CD is classified evolutionary into two phases: an initial acute phase, followed by a chronic
phase. Each phase has distinct clinical characteristics, diagnostic parameters, and treatment
[72–76]. The acute phase is characterized by intense parasitism related with nonspecific symp-
toms, including fever, eyelid edema (denominated Chagoma), edema, and myocarditis. In
general, the progression of disease can take years to reach the chronic phase, which presents
four clinical forms: indeterminate (without clinical manifestations), cardiac, digestive, and
mixed (association of cardiac and digestive) [77–81].
Figure 3. Mechanism of NFX based on nitroreductase type 1 action.
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4.1. Chronic Chagas cardiomyopathy (CCC)
Chronic Chagas cardiomyopathy (CCC) is associated with high rates of morbidity and mortal-
ity, and it is categorized into stages of cardiac impairment (A, B, C, and D) according to the
manifestations, electrocardiograph, radiological alterations, and changes in ventricular func-
tion [72, 74, 75, 82, 83]. Approximately 20–40% of patients with the indeterminate form will
develop CCC. Several mechanisms contribute to this including the persistence of the parasite
and autoimmunity. Moreover, factors such as dysautonomia (neurogenic mechanisms) and
microvascular dysfunctions may potentiate and amplify this damage [74, 75, 77, 79–81, 84].
The cardiac form of Chagas can occur with or without ventricular failure [25, 82, 84]. Although
the most common is the coexistence of arrhythmic manifestations with the congestive form,
some patients have only arrhythmias and intraventricular and atrioventricular conductions
compromising with normal ventricular function. Management of CCC treatment is based on
the following clinical manifestations such as heart failure, cardiac arrhythmia, and thrombo-
embolism [25, 79, 84].
Although, Chagas disease represents an important cause of heart failure (HF), limited studies
have established the use of these drugs in Chagas patients. The treatment of CCC aims to
reduce symptoms, delay the evolution of ventricular dysfunction, and prolong survival. In the
asymptomatic or mild stages of HF, it is intended to delay the evolution of the disease. In the
advanced stages, the objective is to improve the quality of life and the survival of patients. The
efficacy and tolerability of these drugs in patients with CCC is extrapolated from the results
obtained for other etiologies. Therefore, the CCC treatment is suggested to be performed in
accordance with the general guidelines for HF treatment and should consist of the combina-
tion of three therapeutic classes: angiotensin-converting enzyme inhibitors (ACEI) or angio-
tensin receptor blockers (ARB), diuretics, and adrenergic beta blockers (BB) [40, 72, 82].
Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) have
an essential role in adverse cardiac remodeling and ventricular dysfunction progression of HF
[40, 72, 82]. In experimental studies reported in the literature, captopril and enalapril demon-
strated to diminish myocarditis and fibrosis of CCC [85–88]. These drugs should be adminis-
trated initially in low doses. In spite, some physicians report that CCC does not tolerate high
doses of ACEI, according to the degree of tolerability; the dose can be progressively increased
[25, 78, 81]. ACEI is recommended to patients with a left ventricular ejection fraction (LVEF)
<45% [82, 83]. Regarding ARB, spironolactone and eplerenone have been evaluated in studies
and data have shown that these drugs are effective in improving the quality of life and reduction
of symptoms associated with CCC [89–91] and this class is considered as the treatment of choice
for Chagas patients with LVEF <45%, or patients with LVEF<35% and New York Heart Associ-
ation (NYHA) Class III/IV [82, 83]. In addition, in cases that are contraindicated to ACEI and
ARB (hyperkalemia and progressive renal failure), the combination of hydralazine and
isosorbide dinitrate should be prescribed [25, 73, 79, 83].
Beta-adrenergic blockers (carvedilol, bisoprolol, or metoprolol) are suggested in association
with ACEI and ARB due to autonomous nervous system involvement in CCC and the produc-
tion of antibodies against β-1 adrenergic and M-2 muscarinic receptors [25, 73, 79, 83]. Limited
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reports address the efficacy of this therapeutic class to treat Chagas patients with ventricular
dysfunction [86, 92–96]. Beta blockers have been avoided because of the presence of frequent
bradycardia; therefore these drugs are not indicated for patients with bradycardia ≤50 bpm or
AV conduction disorders (PR > 280 ms) [25, 73, 79, 83].
Moreover, digoxin and diuretics are considered a pharmacological option in CCC, justifying
the use of digoxin for patients with symptomatic LVEF ≤45%, principally in the presence of
atrial fibrillation when the ventricular frequency is increased and diuretics to improve conges-
tive symptoms and signs. For advanced HF stages, the combination of thiazides with loop
diuretics has been proven to be more effective [25, 72, 73, 79, 83].
The annual incidence of thromboembolism in Chagas patients is between 1 and 2%, affecting
mainly patients with HF. Occasionally, this aggravation is the first manifestation of the CD.
Cardiac emboli can reach both the pulmonary and systemic circulation, with the cerebral terri-
tory being the most clinically evident [40, 79, 82]. The treatment of thromboembolism is
performed based on the established recommendations, alternating according to the extension
and compromised organ. For this, a score derived from a prospective cohort study with 1043
patients was recently available to evaluate the risk and to implement preventing thromboembo-
lisms in CCC. Through risk-benefit analysis, warfarin is indicated for patients with 4–5 point. In
the case of 3 points, acetylsalicylic acid (AAS) or warfarin could be used. For 2 points, it is
suggested to use AAS or no prophylaxis, and 0–1 points do not need prophylaxis [79, 81, 97].
Patients with CCC usually present ventricular arrhythmia. The most frequent ventricular arrhyth-
mias in Chagas patients are ventricular ectopies, isolated or repetitive. The presence of these
arrhythmias in asymptomatic patients with preserved ventricular function does not require anti-
arrhythmic treatment, whereas in symptomatic cases, the antiarrhythmic treatment can be indi-
vidualized. The goal of pharmacological treatment of arrhythmias is the control of symptoms.
Amiodarone is widely used, despite the high incidence of adverse events. At the usual doses of
200–400 mg/day, it can be associated with alternative agents recommended for cardiopathies of
other etiologies, such as propafenone, sotalol, and beta blockers, to reduce severe arrhythmic
events. However, drugs belonging to class I (sodium-channel blockers) should be avoided, princi-
pally in patients with ventricular dysfunction due to proarrhythmic effects, whereas propafenone
is contraindicated in patients with left ventricular dysfunction [77, 79, 83, 98]. Bradyarrhythmia is
related with sinus node dysfunction or atrioventricular blocks. For the treatment of symptomatic
bradyarrhythmias in CCC, a permanent pacemaker implant is usually performed [98].
4.2. Digestive form of CD
The digestive manifestations of the CD correspond to the functional alterations observed in the
esophagus and intestine, which result in the formation of mega-esophagus or megacolon,
respectively. These deformations are related with the involvement of the enteric nervous
system, especially the Auerbachs plexus. Degenerative phenomena in this region are caused
by the presence of inflammatory processes associated with autoimmune responses. Therefore,
both megacolon and mega-esophagus results in alterations in motility, and consequently, in
slow transit and difficulty to empty, followed by increased organ caliber [99–102].
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Mega-esophagus is classified into four groups with the objective of situating the different
radiological aspects within the evolutionary spectrum of the affection. In addition, the classifi-
cation of the mega-esophagus is important for the choice of treatment [99–101, 103].
The symptoms commonly reported inmega-esophagus are: dysphagia, regurgitation and esoph-
ageal pain. Treatment of mega-esophagus included clinical, pharmacological measures, dilata-
tion and surgical procedure to aid in the transit of foods and liquids. The choice of treatment to
be applied depends on the following factors: patient agreement, relevance of symptoms, degree
of classification, nutritional status, clinical condition, comorbidities, age and available hospital
infrastructure [40, 103, 104].
Clinical and pharmacological treatment is indicated for patients in group I, or patients at
high risk of being treated with other forms of treatment, or in cases refusing invasive
treatment. Patients must frequently drink water during the meals, eat slowly, and give
preference to food in a pasty consistency. Hot and cold foods and drink and eating prior to
bedtime are not recommended because food may be retained in the esophagus, causing
pain or nocturnal regurgitation during sleep. The pharmacological treatment is based on
substances that aim to relax the esophageal sphincter; however, the beneficial effect of these
drugs is restricted to the period of action, being only a symptomatic treatment. The nitric
derivatives (isosorbitol dinitrate) and the calcium channel blockers (nifedipine) are
recommended [40, 101, 104, 105].
Alternative treatment is forced dilation of the distal segment of the esophagus and esophagic
junction using a pneumatic or hydrostatic balloon or surgery. Surgery is performed for patients
classified in group II (according to the intensity of the symptoms), III, and IV, and for patients
without adequate response to clinical treatment. Another alternative is the injection of botuli-
num toxin, which acts to inhibit acetylcholine release [40, 101, 105].
The most frequent symptoms in megacolon consist of intestinal constipations, abdominal
distension discomfort, occlusive phenomena associated with fecaloma, and sigmoid volvulus
[106, 107]. Megacolon treatment may be clinical or surgical and varies according to patient
agreement, level of complications, nutritional status, clinical condition, presence of comorbid-
ity, and age [40]. If the clinical treatment indicates an alteration in the diet, use of laxatives,
such as lubrificant laxatives (mineral oils) and emollient laxatives, and intestinal washes with
water and glycerin may be used [105].
5. Therapeutic alternatives for Chagas disease treatment
5.1. Clinical trials
As previously described in this chapter, a randomized controlled clinical trial for investigation
of BNZ in the treatment of CD was performed only recently: the BENEFIT clinical trial [95].
Therefore, it is not surprising that there is a lack of clinical studies with novel drug candidates
for CD, since even the study to evaluate the first choice treatment is very recent.
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Posaconazole (POS) (Figure 4A) is a triazole derivative with antifungal activity [108], that has been
approved for the treatment of invasive fungal infections in humans [109]. It has shown
trypanocidal activity in murine models [110, 111]. In addition, POS treatment led to the cure of
the infection in one patient, resulting in parasite levels lower than after treatment with BNZ [112].
Therefore, POS efficacy and safety were compared to BNZ in phase II clinical trial CHAGASAZOL
NCT01162967 [4], since it has shown trypanocidal activity in murine models. In this study, 78
patients were randomly selected to receive POS at a dose of 400 mg, POS at a dose of 100 mg, or
BNZ at a dose of 150 mg. All drugs were orally administered twice daily for 60 days. During the
treatment days, only two individual of POS patients treated with the dose of 100 mg had tested
positive for T. cruzi DNA using a RT-PCR assay. The study duration was 1 year, thus the patients
were retested following the treatment period. The outcomes have shown a significantly (p-value
lower than 0.01) higher incidence of positive T. cruziDNA results in both POS-treated groups (81–
92%) compared to BNZ-treated group, since the last one led to only 38% of patients testing positive
for T. cruziDNAusing the RT-PCR assay.While all patients from POS groups completed the study,
five patients stopped the BNZ treatment, due to severe skin reactions. The adverse reactions of the
current treatment with BNZ are some of the reasons why superior treatments must be pursued.
However, BNZ treatment failed in fewer patients than POS [4].
CHAGASAZOL was not the only clinical trial testing the potential application of POS in
Chagas Disease treatment. The clinical trial STOP-CHAGAS NCT01377480 [113] investigated
if POS or POS plus BNZ were superior to BNZ monotherapy in the reduction of parasites load
after 60 days of treatment and 360 days follow up. In this study, 120 subjects were randomly
divided into the following groups: POS 400 mg twice a day; BNZ 200 mg and placebo, both
twice a day; BNZ 200 mg and POS 400 mg, both twice a day; or placebo 10 mg. Two outcome
stages were considered, the persistence of negative RT-PCR in day 180 and the maintenance of
this response by the end of the study in day 360. The successful overall outcome was the RT-
PCR negative result in both stages. Both groups receiving BNZ achieve 96% subjects with
negative RT-PCR at day 360, while placebo group and POS alone group had 16.7% and 23.3%
subjects with negative RT-PCR, respectively. Those groups receiving BNZ also had six serious
adverse events reported, such as cutaneous reactions, nervous system disorders, and gastroin-
testinal symptoms. Therefore once again, BNZ monotherapy was superior to POS, and no
advantages were observed in the combination therapy.
Ravuconazole (Figure 4C) is another triazole compound that has shown potent and specific
anti-T. cruzi action in vitro, but with limited in vivo activity, probably as a consequence of its
poor pharmacokinetic properties [114]. Therefore, E1224 (Figure 4D) was developed as a
prodrug of ravuconazole. A phase II Clinical Trial was performed in 2013 to evaluate the
prodrug efficacy and safety compared to BNZ, as a randomized double-blinded placebo-
controlled proof-of-concept study [115]. The study was performed in 224 patients with chronic
indeterminate CD. Two groups received E1224 for 60 days at doses of 200 mg (low dose) and
400 mg (high dose), one group took E1224 for 30 days at a dose of 400 mg (short dose), and one
group received BNZ at dose of 5 mg/kg/day. All treatments were able to eliminate blood-
circulating parasites during the treatment period. E1224 had a parasite clearance rate of 90,
89, and 76% for the low dose group, short dose group, and high dose group, respectively.
However, at the 12-month evaluation clearance of all patients that received E1224 was signif-
icantly low, and only the high dose group (29%) led to results significantly better than placebo.
Chagas Disease - Basic Investigations and Challenges132
Alternatively, the BNZ clearance was 91% at 60 days after treatment and it dropped to 82% at
12 months, also being significant versus placebo. In summary, the drug candidate E1224 was as
effective as BNZ at clearing the parasite following the treatment course, but the sustained
efficacy 1 year following treatment was very low. Further, BNZ led to significant side effects.
Therefore E1224, now called fosravuconazole, will be clinically tested in association to BNZ in
order to improve treatment tolerability issues by combining them in the disease therapy.
A search for CD studies of new treatments on the clinical trials website (clinicaltrials.gov) pro-
vides one more study, with fexinidazole (Figure 4B). This compound is an old nitroimidazole
that has shown promising results in preclinical models of CD [116]. According to Drug for
Neglected Disease initiative (DNDi), this clinical study NCT02498782 was stopped due to safety
and tolerability issues that occurred at the highest tested dose. High efficacy was observed at the
lowest dose with acceptable safety and tolerability. Based on this, DNDi claims to be planning a
new study in the near future [117].
5.2. Preclinical studies
Considering the lack of new and safer treatment options for CD, it is very encouraging to observe
the efforts of many research groups investigating suitable candidates, which may improve the
quality of life of many Chagas disease patients. Among the proposed targets for new alternative
therapies examples are, ergosterol synthesis, cruzipain, trypanothione reductase, and type I
Figure 4. Structures of the compounds posaconazole (A), fexinidazole (B), ravuconazole (C), and E1224/fosravuconazole
(D).
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nitroreductase. Studies addressing these targets in several phases of development will be
discussed in this text. However, only a few compounds have demonstrated in vivo activity and
favorable disposition, while none of the published preclinical candidates seems to be in the
boundary of the clinical studies.
5.2.1. CYP51
The sterol 14α-demethylase (CYP51) is an important enzyme for T. cruzi survival [118], which
works as a target of broad-spectrum antifungal agents, such as POS and ravuconazole, or its
prodrug fosravuconazole [119]. Since they were clinically tested, as previously mentioned,
they are the most close that a new treatment has come to the patients, even though the clinical
studies outcomes were not the best [113]. Albaconazole was considered promising after in vitro
and in vivo studies, but its effect was not satisfactory against a resistant strain [120, 121].
Several others inhibitors of sterol biosynthesis have been tested in non-clinical phases. TAK-187
is another antifungal agent [122] tested for CD due to its good drug-like properties and mecha-
nism of action aiming at CYP51. It has shown potent anti-T. cruzi activity in vitro and in vivo
[122], while preventing Trypanosoma cruzi-induced cardiac damage [123]. Recently, a new formu-
lation of TAK-187 was patented [124], indicating that a clinical study is potentially possible.
Dialkyl imidazoles have shown high potency (EC50 in the 0.4–10 nM range) against T. cruzi
in vitro, leading two of them to be tested in vivo [125]. These derivatives were able to reduce the
parasitemia to undetectable levels in a mouse model of acute CD. According to the authors,
these compounds are less expensive to be produced than POS. Carrying systematic modifica-
tions in the proposed scaffold of the aforementioned candidates led to new candidates with an
EC50 better than that of POS (1 nM); however, only in vitro studies have been performed [126].
Since tipifarnib has shown potent anti-T. cruzi activity, it is being considered as a new lead
compound for CD treatment [127]. To evaluate this drug, analogs of the antitumor agent were
designed and investigated in vitro. They were considered advantageous due to their modest
potency for inhibition of human CYP3A4 [128]. One of these analogs, compound 2 was evaluated
in vivo, but was not better than POS or BNZ [129]. Lack of adequate pharmacokinetic properties,
with short half-life and low exposure, may cause the tipifarnib analog to be ineffective.
A very rational study was performed in the development of 4-aminopyridyl-based CYP51
inhibitors [130]. In this study, compounds were developed and tested for their in vitro activity.
To assess their action in vivo, the pharmacokinetic study was previously performed to better
understand the compounds disposition and modify the vehicle of administration. Some of the
derivatives have demonstrated better in vivo activity when compared to the in vitro studies. For
the authors, the disconnection between in vitro and in vivo potency raised questions about
prioritizing the CYP inhibitors based only on their in vitro performance. They achieved lead
compounds with good potency and oral bioavailability, while they admit the need for optimi-
zation of the elimination half-lives.
A similar study design was followed to evaluate analogs of fenarimol [131], where it was
observed that compounds with long half-lives, that is, maintaining plasma concentration
above the IC50, were those that led to undetectable parasite levels in bloodstream. The
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compounds that were less effective to reduce the parasitemia were those with fast elimination
and plasma concentrations equals or below the IC50. The two lead compounds were highly
bioavailable with a long half-life. The in vivo efficacy was superior compared to BNZ and
comparable to POS.
Assuming an evolution of the antifungal approach, VNI is an imidazol developed to be
specifically active in the inhibition of the CYP51 of T. cruzi. It was able to cure the acute and
chronic forms of CD in mice, with 100% survival and no observable side effects. Its pharmaco-
kinetics were considered suitable for further development; however, the presented data were
not completely explored [132]. The VNI optimization, VFV, overcame the promising results of
VNI not only in the animal model of CD cure rate, but also with better pharmacokinetic
properties and more information regarding distribution and biotransformation [133]. The
reporting of VFV acute toxicity study have shown no observed adverse effect up to 200 mg/
kg in mice, but authors did not present data to assure that the absorption was not saturated,
that is, the exposure was proportional to the doses used in the acute toxicity study [134]. These
imidazole-containing compounds seem to be the most advanced compounds, but the authors
highlight the need for further studies.
5.2.2. Cruzipain
The cysteine proteinase cruzipain is vital for T. cruzi survival, since it is essential for the
parasite replication and differentiation. Based on this, cruzipain has been considered as a
target for drug discovery, but also for vaccines [135]. Phe-ala-PQ was a prodrug of primaquine,
which had the intent to use the proteinase function of cruzipain to release the parent molecule
in the parasite [136], but there are others.
Vinyl-sulfone derivatives [137], such as K11777 and WRR-483 have irreversible inhibitory
activity in cruzipain, leading them to be effective against T. cruzi in vitro and, also in vivo [138,
139]. On the other hand, Cz007 and Cz008 are vinyl-sulfones containing nitrile with reversible
cysteine proteinase activity that showed in vivo anti-T. cruzi action following oral administra-
tion in a dose lower than that of BNZ [140, 141]. Authors report bioavailability of both new
compounds to be approximately 50%, but with short elimination half-life, what led them to
administer the compounds for the efficacy study mixed to powdered chow, while BNZ was
administered in water.
Additional compounds focusing on cruzipain have their anti-trypanocidal activity published
only in vitro, such as thiazolyl hydrazones [142], thio semicarbazones [143], acylhydrazones
[144], dipeptidyl nitrile derivatives [145], and triazine and purine nitriles [146].
5.2.3. Trypanothione reductase
Trypanothione reductase is responsible for the parasite antioxidant protective mechanism,
thus inhibitors aiming for this target may disrupt its antioxidant defenses [147]. Some tricyclic
compounds already active for other conditions were able to inhibit trypanothione reductase,
and clomipramine was the most active with an inhibition constant (Ki) of 6 μM [148]. The
testing for new active compounds led to the discovery of inhibitors with a Ki up to 0.33 μM
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[149]. Among the phenothiazines, thioridazine is one of the most potent irreversible inhibitors
of trypanothione reductase [150], and has shown better in vivo activity than the non-treated
group [151]. When compared to BNZ, thioridazine animal survival was comparable of BNZ in
mice infected with T. cruzi [152].
Moreover the trypanothione reductase inhibition, hydroxymethyl nitrofurazone (NFOH) is
able to inhibit cruzipain by 60%, showing in vivo activity and experimental animal survival
comparable to BNZ [153]. The NFOH pharmacokinetics were studied in rats and rabbits [154,
155], and indicated that optimization is needed despite the dual action.
Additional compounds able to inhibit trypanothione reductase in vitro include quaternary ana-
logs [156] of chlorpromazine. The dibenzosuberyl-containing analogs of clomipramine were
poor inhibitors of trypanothione reductase, while the polyamine derivatives containing
dibenzosuberyl were potent inhibitors up to 0.26 μM, even though they were not active in vivo,
maybe due to poor pharmacokinetic properties, which were not evaluated [157]. Studying the
in vitro anti-T. cruzi activities of ethyl and methyl quinoxaline-7-carboxylate 1,4-di-N-oxide
derivatives, three compounds were discovered. However, only one was non-cytotoxic on host
macrophage cells [158], and no in vivo study was presented.
5.2.4. Type I nitroreductase
Type I nitroreductase is an enzyme responsible for the differentiation of T. cruzi and for the
activation of nitroheterocycles [159]. Nitroreductases are among the enzymes proposed as
responsible for the bioactivation of BNZ [159] and NFX [160]. Based on this hypothesis, the
impairment of this enzyme would be responsible for resistance [159].
The type I nitroreductase bioactivation approach supports the in vitro action of aziridinyl
nitrobenzamide [161] and halogenated nitrobenzylphosphoramide mustards [162] prodrugs;
however, the last was assessed in T. brucei parasites. Several nitrotriazole-based compounds
demonstrated significant in vitro antichagasic activity [163, 164]. Further studies identified com-
pounds with promising in vivo activity that has shown good in vitro ADME properties [165].
Nitrotriazole compounds with dual action aiming type I nitroreductase and inhibition of
CYP51 were able to clear the parasites following a 10-day treatment, better than what was
observed in the previous mentioned monofunctional 3-nitrotriazole-based derivatives [166].
Prior to the positive results of the dual action compounds, some experiments led to the
understanding that nitroheterocylic compounds are better than those able to inhibit ergosterol
biosynthesis [167], while it seems that together, they can work better.
Many preclinical candidates have only proven to be effective in silico or in vitro becoming
promising leads or proving the validity of the proposed strategy. Novel drug candidates with
in vivo activity, in limited cases have published disposition data, such as bioavailability and
elimination half-life. The crucial study before clinical studies is the achievement of the NOAEL,
since it is necessary to calculate the first in human dose. However, for compounds not showing
clear toxicity without the pharmacokinetic assessment, the NOAEL can be overestimated due
to saturated absorption, and this can be an challenge for compounds without this data [168].
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5.2.5. Combined alternatives in preclinical studies
Based on the safety issues of BNZ and NFX, strategies to reduce their administered amount
would prove beneficial as it may decrease the adverse effects. To circumvent the decrease in
efficacy due to dose reduction, combined therapies have been proposed.
The combination of the diamidine prodrug DB289 and BNZ orally decreased parasitemia by
99%, while alone they led to 70 and 90% for DB289 and BNZ, respectively. When the combina-
tion of BNZ and DB766 was administered, the decrease in the parasitemia was at least 99.5%.
Both combined treatments provided 100% protection against mice mortality, while BNZ alone
provided only 78% protection [169].
The combination of BNZ and ketoconazole were evaluated in a disease mouse model. This led
to better results than single treatments with susceptible and moderately resistant (Y) strains of
T. cruzi. [170]. The same Y strain of T. cruzi in vivowas used to evaluate the combination of BNZ
and itraconazole and the results indicated a fourfold improvement in the disease outcome
against each single treatment. Additionally, this combination led to a decrease in cardiotoxicity
in the experimental CD [171].
The new compound tetrahydro-β-carboline N-butyl-1-(4-dimethylamino)phenyl-1,2,3,4-
tetrahydro-β-carboline-3-carboxamide was superior among its peers in reducing the number
of infected cells and the number of internalized parasites, with low cytotoxicity [172]. After
this observation, the selected compound was evaluated in combination with BNZ in vitro
and in vivo, where a synergic effect was observed, leading to a reduction in parasitemia and
mortality rates [173].
An additional compound tested with BNZ was the new drug candidate 2-methyl-1,5-bis(4-
nitrophenyl)penta-1,4-dien-3-one, which has shown trypanocidal activity in vitro. Next, it was
evaluated in combination with BNZ, ketoconazole, and fluconazole. Although the combina-
tion with the last one was ineffective, the combination with BNZ and ketoconazole demon-
strated strong synergism [174].
These studies indicate that combination of new compounds or compounds used for alternative
conditions have the potential to be a successful approach. A similar strategy has been planned
for clinical trials to evaluate the combination of benznidazole and fosravuconazole, despite the
absence of advantage in the combined therapy using BNZ and POS.
6. Conclusion
Once no new therapeutic alternatives have been included in its treatment portfolio after
benznidazole and nifurtimox introduction there is a need for new compounds able to treat
patients of CD. Many new drug candidates are evaluated to provide a better treatment for
patients in the chronic phase. Benznidazole and nifurtimox are very effective, but their adverse
effects cause many patients to discontinue treatment. Symptomatic treatment of the chronic
phase of the disease is as important as the treatment directed in the reduction of the parasite. It
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is necessary to evaluate the patient conditions correctly to improve the quality of life. It is
comprehensible that the chase for new options against this disease begins with a search of new
molecules, but it is important to keep in mind that this is just a small step. Significance can only
be measured if the following steps are performed and the patient treatment is reached. The
combined therapy and the repurposing approaches may discover the next treatment option;
however, the research must not be completed until the ideal treatment is achieved.
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